Evaluating the effect of black myrobalan on cognitive, positive, and negative symptoms in patients with chronic schizophrenia: A randomized, double‐blind, placebo‐controlled trial

2021 ◽  
Author(s):  
Mohammad Banazadeh ◽  
Mitra Mehrabani ◽  
Nabi Banazadeh ◽  
Fatemeh Dabaghzadeh ◽  
Farzad Shahabi
Keyword(s):  
Negative Symptoms ◽  
Controlled Trial ◽  
Chronic Schizophrenia ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Positive And Negative Symptoms

Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: A randomized double-blind placebo-controlled trial

2010 ◽  
Vol 179 (1) ◽  
pp. 19-23 ◽  
Author(s):  
Iulian Iancu ◽  
Eleonora Tschernihovsky ◽  
Ehud Bodner ◽  
Anna Sapir Piconne ◽  
Katherine Lowengrub
Keyword(s):  
Negative Symptoms ◽  
Controlled Trial ◽  
Chronic Schizophrenia ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial

2018 ◽  
Vol 5 (11) ◽  
pp. 885-894 ◽  
Author(s):  
Bill Deakin ◽  
John Suckling ◽  
Thomas R E Barnes ◽  
Kelly Byrne ◽  
Imran B Chaudhry ◽  
...  
Keyword(s):  
Negative Symptoms ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Recent Onset

Double-Blind, Placebo-Controlled, Crossover Trial of Glycine Adjuvant Therapy for Treatment-Resistant Schizophrenia

1996 ◽  
Vol 169 (5) ◽  
pp. 610-617 ◽  
Author(s):  
Uriel Heresco-Levy ◽  
Daniel C. Javitt ◽  
Marina Ermilov ◽  
Clara Mordel ◽  
Avraham Horowitz ◽  
...  
Keyword(s):  
Cognitive Deficits ◽  
Negative Symptoms ◽  
Crossover Trial ◽  
Chronic Schizophrenia ◽  
Antipsychotic Treatment ◽  
Treatment Resistant ◽  
Double Blind ◽  
Baseline Serum ◽  
Double Blind Placebo ◽  
Additional Approach

BackgroundIt has been proposed that schizophrenia is associated with underactivity of brain glutamatergic neurotransmission, especially at the level of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor. Glycine potentiates NMDA receptor-mediated neurotransmission, indicating that it may serve as an effective therapeutic agent in the treatment of schizophrenia.MethodEleven treatment-resistant patients with chronic schizophrenia completed a double-blind placebo-controlled, six-week, randomly assigned, crossover treatment trial of 0.8 g/kg body weight/day of glycine, added to their prior antipsychotic treatment.ResultsGlycine was well tolerated, resulted in significantly increased serum glycine levels and induced a mean 36 (7%) reduction in negative symptoms (P < 0.0001). Significant improvments were also induced in depressive and cognitive symptoms. The greatest reduction in negative symptoms was registered in the patients who had the lowest baseline serum glycine levels.ConclusionsThese results extend previous findings and suggest an additional approach to the pharmacotherapy of negative symptoms and cognitive deficits in schizophrenia.

A Randomized, Double-Blind, Placebo-Controlled Trial of Modafinil for Negative Symptoms in Schizophrenia

2007 ◽  
Vol 68 (05) ◽  
pp. 705-710 ◽  
Author(s):  
Joseph M. Pierre ◽  
John H. Peloian ◽  
Donna A. Wirshing ◽  
William C. Wirshing ◽  
Stephen R. Marder
Keyword(s):  
Negative Symptoms ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Amisulpride Augmentation Therapy Improves Cognitive Performance and Psychopathology in Clozapine-resistant Treatment-refractory Schizophrenia (CTRS): a 12-week Randomized, Double-blind, Placebo-controlled Trial

2022 ◽  
Author(s):  
Zezhi Li ◽  
Minghuan Zhu ◽  
Zhenjing Liu ◽  
Qiongyue Hu ◽  
Jiayu Yang ◽  
...  
Keyword(s):  
Placebo Group ◽  
Cognitive Function ◽  
Cognitive Performance ◽  
Negative Symptoms ◽  
Psychiatric Symptoms ◽  
Controlled Trial ◽  
Augmentation Therapy ◽  
Laboratory Measurements ◽  
Double Blind ◽  
Double Blind Placebo

Abstract BackgroundAlthough clozapine is an effective option for treatment-resistant schizophrenia (TRS), there are still 1/3 to 1/2 of TRS patients who do not respond to clozapine. The main purposes of this randomized, double-blind, placebo-controlled trial was to explore the amisulpride augmentation efficacy on the psychopathological symptoms and cognitive function of CTRS patients. MethodsA total of 80 patients were recruited and randomly assigned to receive an initial clozapine plus amisulpride or clozapine plus placebo. Positive and Negative Syndrome Scale (PANSS), Scale for the Assessment of Negative Symptoms (SANS), Clinical Global Impression (CGI) scale scores, Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Treatment Emergent Symptom Scale (TESS), laboratory measurements and electrocardiograms (ECG) were performed at baseline, week 6, and week 12. ResultsCompared with clozapine plus placebo group, clozapine plus amisulpride had lower PANSS total score, positive subscore and general psychopathology subscore at week 6 and week 12 (all p Bonferroni< 0.01). Furthermore, compared with clozapine plus placebo group, clozapine plus amisulpride showed improved RBANS language score at week 12 (p Bonferroni< 0.001). Clozapine plus amisulpride group had a higher treatment response rate (p = 0.04), lower scores of CGI severity (CGI-S) and CGI efficacy (CGI-E) at week 6 and week 12 than clozapine plus placebo (all p Bonferroni< 0.05). There were no differences in BMI, QT intervals or laboratory measurements between the groups. Our results demonstrate that amisulpride augmentation therapy can safely improve the psychiatric symptoms and cognitive performance of CTRS patients. ConclusionsOur study indicates that amisulpride augmentation therapy has important clinical significance for the treatment of CTRS to improve clinical symptoms and cognitive function with tolerability and safety.Trial registrationClinicaltrials.gov identifier- NCT03652974. Registered 31 August 2018, https://clinicaltrials.gov/ct2/show/NCT03652974

Sign in / Sign up

Export Citation Format

Share Document